VYNE recently announced positive results for its novel oral small molecule BD2-selective BET inhibitor in a single-ascending dose clinical trial.
Iain Stuart, PhD
Advertisement
Articles by Iain Stuart, PhD
Iain Stuart, PhD, discusses VYN202's status and potential in psoriasis and immuno-inflammatory diseases.
VYNE Therapeutics' Iain Stuart, PhD, spoke with Dermatology Times to discuss recent phase 1 and pre-clinical data for VYN201 for vitiligo.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Dermalogica Enters Medical Aesthetics with FDA-Cleared Microneedling PRO Pen
2
Social Media Mythbusters: Hypochlorous Acid Sprays
3
SkinJect Advances into Registrable Development as Potential First-in-Class Therapy for Gorlin Syndrome
4
STAT6 Degradation by KT-621 Correlates With Itch and Lesion Reduction in AD
5